28599-52-2

Basic information

• Product Name: 5-BROMO-2,4-DIMETHYL-1,3-THIAZOLE
• Synonyms: 5-BROMO-2,4-DIMETHYL-1,3-THIAZOLE;5-bromo-2,4-dimethylthiazole;Thiazole,5-bromo-2,4-dimethyl-
• CAS NO: 28599-52-2
• Molecular Formula: C₅H₆BrNS
• Molecular Weight: 192.08
• EINECS: 200-258-5
• Product Categories: Thiazole series
• Mol File: 28599-52-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 153-155 °C
• Boiling Point: 221.082 °C at 760 mmHg
• Flash Point: 87.507 °C
• Appearance: /
• Density: 1.589 g/cm³
• Vapor Pressure: 0.162mmHg at 25°C
• Refractive Index: 1.577
• PKA: 2.93±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2,4-DIMETHYL-1,3-THIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2,4-DIMETHYL-1,3-THIAZOLE(28599-52-2)
• EPA Substance Registry System: 5-BROMO-2,4-DIMETHYL-1,3-THIAZOLE(28599-52-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• Hazardous Substances Data: 28599-52-2(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powde

InChI:InChI=1/C5H6BrNS/c1-3-5(6)8-4(2)7-3/h1-2H3

Upstream product

• 541-58-2 2,4-dimethylthiazole 

Downstream Products

• 89775-33-7 1-(2,4-dimethyl-thiazol-5-yl)-ethanol 
• 13623-11-5 2,4,5-trimethylthiazole 
• 50382-32-6 (2,4-dimethyl-1,3-thiazol-5-yl)methanol 
• 53137-27-2 2,4-dimethyl-thiazole-5-carboxylic acid 
• 859833-13-9 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole 
• 1201194-99-1 (2,4-dimethyl-thiazol-5-yl)-(2-p-tolyl-ethyl)-amine 
• 90672-63-2 1-[(2-Chloro-phenyl)-(2,4-dimethyl-thiazol-5-yl)-methyl]-4-methyl-piperazine 

Relevant articles and documents

PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR

The present invention discloses a series of pyrazolopyrimidine derivatives and use thereof in preparing a medicament for treating a disease related to PI3K, and in particular, discloses a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g.,leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. (I)

Photochromism of new diarylethenes bearing both thiazole and benzene moieties

A new class of photochromic diarylethenes bearing both thiazole and benzene moieties has been developed, and the effects of substitution on their properties, including photochromism, fatigue resistance, and fluorescence properties have been investigated.